NCT05428969
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05428969
Title A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (BEXMAB)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Faron Pharmaceuticals Ltd
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | GBR | FIN

Facility Status City State Zip Country Details
City of Hope National Medical Center Duarte California 91010 United States Details
Yale Cancer Center New Haven Connecticut 06510 United States Details
UNC Lineberger Comprehensive Cancer Center Chapel Hill North Carolina 27599 United States Details
University of Texas, MD Anderson Cancer Center Houston Texas 77030 United States Details
Helsinki University Hospital Helsinki 00029 Finland Details
Kuopio University Hospital Kuopio 70210 Finland Details
Oulu University Hospital Oulu 90029 Finland Details
Tampere University Hospital Tampere 33520 Finland Details
The Christie NHS Foundation Trust Manchester United Kingdom Details
Royal Cornwall Hospitals NHS Trust Truro United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field